Travere Therapeutics TVTX announced that the FDA granted full approval to its oral non-immunosuppressive drug Filspari ...

Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Atrasentan hydrochloride is a small molecule commercialized by Novartis, with a leading Pre-Registration program in IgA Nephropathy (Berger's Disease).

Returning to Boston this December, the 4th annual Rare & Genetic Kidney Disease Drug Development Summit will unite 30+ experts speakers including Novartis, FDA, XORTX Therapeutics, Walden Biosciences, ...

One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney ...

Advancements and Projections in the Antibody Drug Conjugates Market: Insights, Trends, Opportunities, and Recent ...

The New York Times: Deep Links Between Alcohol And Cancer Are Described In New Report Adults under age 50 have been developing breast cancer and colorectal cancer at increasingly higher rates ...

Replimune's cash runway supports its accelerated approval and phase 3 trial. See why I think REPL's current low stock price ...

Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis.